Published in Ann Oncol on November 12, 2007
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol (2010) 2.94
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer (2010) 1.91
Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment. Proc Natl Acad Sci U S A (2011) 1.62
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging (2011) 1.50
Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Cancer Res (2012) 1.28
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br J Cancer (2014) 1.08
18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol (2011) 1.07
Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res (2009) 1.04
Breast Cancer: State of the Art and New Findings. Geburtshilfe Frauenheilkd (2012) 1.01
The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation. PLoS One (2014) 0.97
Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology (2011) 0.97
Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surgery (2012) 0.95
Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results. Magn Reson Imaging (2013) 0.94
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. Br J Cancer (2010) 0.92
Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer. Ann Surg (2009) 0.87
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Res (2016) 0.86
Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy. Biomed Opt Express (2012) 0.85
Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy. J Oncol (2013) 0.84
Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics (2011) 0.83
Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. PLoS One (2014) 0.82
Reduced Let-7a Is Associated with Chemoresistance in Primary Breast Cancer. PLoS One (2015) 0.81
Towards non-invasive characterization of breast cancer and cancer metabolism with diffuse optics. PET Clin (2013) 0.81
Distribution of breast cancer subtypes among Jordanian women and correlation with histopathological grade: molecular subclassification study. JRSM Short Rep (2013) 0.81
Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction-Diffusion Model. Cancer Res (2015) 0.81
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy. Eur J Nucl Med Mol Imaging (2010) 0.80
Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol (2013) 0.80
Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer. PLoS One (2013) 0.80
Ultrasonography-guided surgical clip placement for tumor localization in patients undergoing neoadjuvant chemotherapy for breast cancer. J Breast Cancer (2015) 0.80
Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med (2016) 0.80
Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy. Biomed Res Int (2013) 0.79
Patterns of Care for Localized Breast Cancer in Oklahoma, 2003-2006. Women Health (2015) 0.79
Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer. J Korean Surg Soc (2013) 0.79
Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. Br J Cancer (2008) 0.78
Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction. JAMA Surg (2014) 0.78
Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series. Breast Cancer (Dove Med Press) (2015) 0.78
Main complications and results of treatment with intra-arterial infusion chemotherapy through the subclavian and thoracic arteries for locally advanced breast cancer. Mol Clin Oncol (2013) 0.77
Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy? Biomed Res Int (2014) 0.77
Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. Breast Cancer (2014) 0.77
The Value of Combined Large Format Histopathology Technique to Assess the Surgically Removed Breast Tissue following Neoadjuvant Chemotherapy: A Single Institution Study of 40 Cases. Int J Breast Cancer (2012) 0.76
The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy. Breast Cancer Res (2013) 0.76
Bootcamp during neoadjuvant chemotherapy for breast cancer: a randomized pilot trial. Breast Cancer (Auckl) (2012) 0.76
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study. BMC Cancer (2015) 0.75
Neoadjuvant chemotherapy and pathologic response: a retrospective cohort. Einstein (Sao Paulo) (2013) 0.75
In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy? Oncologist (2015) 0.75
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl (2013) 0.75
Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature. Oncol Lett (2016) 0.75
Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer. Front Oncol (2013) 0.75
Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period. J Pathol Transl Med (2016) 0.75
Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects. Springerplus (2014) 0.75
Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer. Breast Care (Basel) (2011) 0.75
Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients? Eur J Nucl Med Mol Imaging (2012) 0.75
Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer. ISRN Oncol (2013) 0.75
Preoperative Radiotherapy Is Not Associated with Increased Post-mastectomy Short-term Morbidity: Analysis of 77,902 Patients. Plast Reconstr Surg Glob Open (2017) 0.75
A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer. Transl Oncol (2017) 0.75
Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers. Oncotarget (2017) 0.75
RNA Sequencing Uncovers Molecular Mechanisms Underlying Pathological Complete Response to Chemotherapy in Patients with Operable Breast Cancer. Med Sci Monit (2017) 0.75
Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer. Virchows Arch (2016) 0.75
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
Basic local alignment search tool. J Mol Biol (1990) 659.07
A greedy algorithm for aligning DNA sequences. J Comput Biol (2000) 47.89
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Optimal alignments in linear space. Comput Appl Biosci (1988) 38.10
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Protein sequence similarity searches using patterns as seeds. Nucleic Acids Res (1998) 23.87
The UCSC Genome Browser Database: 2008 update. Nucleic Acids Res (2007) 23.13
A computer program for aligning a cDNA sequence with a genomic DNA sequence. Genome Res (1998) 22.69
Aligning two sequences within a specified diagonal band. Comput Appl Biosci (1992) 19.31
PipMaker--a web server for aligning two genomic DNA sequences. Genome Res (2000) 17.46
Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature (2001) 16.89
Comparative analyses of multi-species sequences from targeted genomic regions. Nature (2003) 13.31
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. Science (2000) 10.14
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol (1998) 9.32
Long human-mouse sequence alignments reveal novel regulatory elements: a reason to sequence the mouse genome. Genome Res (1997) 8.49
Scoring pairwise genomic sequence alignments. Pac Symp Biocomput (2002) 8.42
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
Comparison of DNA sequences with protein sequences. Genomics (1997) 7.76
Mapping sequenced E.coli genes by computer: software, strategies and examples. Nucleic Acids Res (1991) 6.29
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
Large-scale comparative sequence analysis of the human and murine Bruton's tyrosine kinase loci reveals conserved regulatory domains. Genome Res (1997) 4.82
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol (1999) 4.79
Alignment of Escherichia coli K12 DNA sequences to a genomic restriction map. Nucleic Acids Res (1990) 4.07
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med (1992) 4.05
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol (2000) 4.03
Comparative sequence analysis of a gene-rich cluster at human chromosome 12p13 and its syntenic region in mouse chromosome 6. Genome Res (1998) 3.80
Locus control regions of mammalian beta-globin gene clusters: combining phylogenetic analyses and experimental results to gain functional insights. Gene (1997) 3.77
The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med (1977) 3.61
A local alignment tool for very long DNA sequences. Comput Appl Biosci (1995) 3.58
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood (1997) 3.56
CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet (1995) 3.07
Post-processing long pairwise alignments. Bioinformatics (1999) 3.00
A space-efficient algorithm for local similarities. Comput Appl Biosci (1990) 2.98
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
Modulation of the two promoters of the galactose operon of Escherichia coli. Nature (1979) 2.91
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr (2010) 2.91
Comparative analysis of the gene-dense ACHE/TFR2 region on human chromosome 7q22 with the orthologous region on mouse chromosome 5. Nucleic Acids Res (2001) 2.89
Polycystic ovaries treated by laparoscopic laser vaporization. Fertil Steril (1989) 2.77
Analysis of the quality and utility of random shotgun sequencing at low redundancies. Genome Res (1998) 2.74
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer (2008) 2.67
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol (2010) 2.64
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer (2001) 2.58
Correlation of the highest-energy cosmic rays with nearby extragalactic objects. Science (2007) 2.57
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol (2013) 2.57
Metabolism of (14C) cefaclor, a cephalosporin antibiotic, in three species of laboratory animals. Antimicrob Agents Chemother (1976) 2.52
Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst (1996) 2.51
Comparative genome analysis delimits a chromosomal domain and identifies key regulatory elements in the alpha globin cluster. Hum Mol Genet (2001) 2.46
Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood (1990) 2.38
Globin gene server: a prototype E-mail database server featuring extensive multiple alignments and data compilation for electronic genetic analysis. Genomics (1994) 2.36
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Impact of smoking on mortality and life expectancy in Japanese smokers: a prospective cohort study. BMJ (2012) 2.28
Comparison of five methods for finding conserved sequences in multiple alignments of gene regulatory regions. Nucleic Acids Res (1999) 2.19
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1999) 2.19
Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacin. Antimicrob Agents Chemother (1989) 2.17
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol (2012) 2.16
The Small Area Health Statistics Unit: a national facility for investigating health around point sources of environmental pollution in the United Kingdom. J Epidemiol Community Health (1992) 2.15
Comparison of the Escherichia coli K-12 genome with sampled genomes of a Klebsiella pneumoniae and three salmonella enterica serovars, Typhimurium, Typhi and Paratyphi. Nucleic Acids Res (2000) 2.07
Quality of care of VLBW neonates: relationship between unit volume and outcome is different between metropolitan and rural regions. Acta Paediatr (2008) 2.04
AH/PH domain-mediated interaction between Akt molecules and its potential role in Akt regulation. Mol Cell Biol (1995) 2.03
Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia (2001) 2.02
Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase. Proc Natl Acad Sci U S A (1994) 2.00
Characterization of the human and mouse unconventional myosin XV genes responsible for hereditary deafness DFNB3 and shaker 2. Genomics (1999) 1.97
A tool for aligning very similar DNA sequences. Comput Appl Biosci (1997) 1.97
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer (2001) 1.96
Alignments without low-scoring regions. J Comput Biol (1998) 1.96
Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A (1993) 1.95
Comparative sequence of human and mouse BAC clones from the mnd2 region of chromosome 2p13. Genome Res (1999) 1.94
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol (2010) 1.91
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer (2003) 1.90
Diabetes mellitus: an underestimated public health program. J Chronic Dis (1975) 1.87
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol (1995) 1.87
Sequence and comparative analysis of the mouse 1-megabase region orthologous to the human 11p15 imprinted domain. Genome Res (2000) 1.85
Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res (1995) 1.83
New prognostic factors for breast cancer recurrence. Semin Oncol (2001) 1.77
Chaining multiple-alignment blocks. J Comput Biol (1994) 1.75
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol (2009) 1.71
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst (2001) 1.71
Genome sequence comparisons: hurdles in the fast lane to functional genomics. Brief Bioinform (2000) 1.71
MR imaging of the breast with Gd-DTPA: use and limitations. Radiology (1989) 1.70
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol (2012) 1.69
Accuracy of bedside chest hard-copy screen-film versus hard- and soft-copy computed radiographs in a medical intensive care unit: receiver operating characteristic analysis. Radiology (1997) 1.69
Software tools for analyzing pairwise alignments of long sequences. Nucleic Acids Res (1991) 1.68
Approximate matching of regular expressions. Bull Math Biol (1989) 1.68
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer (1996) 1.67